Intensivierte Insulintherapie

Schlüsselwörter

Diabetes mellitus - intensivierte Insulintherapie - Indikationen - praktische Durchführung - Limitationen

Key words

diabetes mellitus - intensified insulin therapy - indications - practical advise - limitations

Literatur

• 1 Berthe E, Lireux B, Coffin C. et al . Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure.  Horm Metab Res. 2007;  39 224-9
• 2 Bott S, Bott U, Berger M, Mühlhauser I. Intensified insulin therapy and the risk of severe hypoglycaemia.  Diabetologia. 1997;  40 926-32
• 3 Cryer P E, Davis S N, Shamoon H. Hypoglycemia in diabetes.  Diabetes Care. 2003;  26 1902-12
• 4 Devries J H, Nattrass M, Pieber T R. Refining basal insulin therapy: what have we learned in the age of analogues?.  Diabetes Metab Res Rev. 2007;  23 441-54
• 5 Dornhorst A, Lüddeke H J, Honka M. et al . Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients.  Curr Med Res Opin. 2007 Dec 19 [Epub ahead of print]; 
• 6 Dreyer M. Rationale und rationelle Insulintherapie für Patienten mit Typ-1 Diabetes.  Diabetologie. 2007;  2 R41-R56
• 7 Gaede P, Lund-Andersen H, Parving H H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes.  N Engl J Med. 2008;  358 580-91
• 8 Garber A J, Clauson P, Pedersen C B, Kølendorf K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.  J Am Geriatr Soc. 2007;  55 1735-40
• 9 Hauner H, Hanisch J, Bramlage P. et al . Prevalence of Undiagnosed Type-2-Diabetes Mellitus and Impaired Fasting Glucose in German Primary Care: Data from the German Metabolic and Cardiovascular Risk Project (GEMCAS).  Exp Clin Endocrinol Diabetes. 2007 Oct 9 [Epub ahead of print]; 
• 10 Heise T, Nosek L, Rønn B B, Endahl L, Heinemann L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin Glargin in people with type 1 diabetes.  Diabetes. 2004;  53 1614-20
• 11 Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?.  Diabetes Obes Metab. 2007;  9 209-17
• 12 Hummel M, Füchtenbusch M. Diabetes mellitus - differential diagnosis.  MMW Fortschr Med. 2006;  148 47-50
• 13 Lalli C, Ciofetta M, Del S indaco P. et al . Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.  Diabetes Care. 1999;  22 468-77
• 14 Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus.  BMJ. 1997;  314 1512-5
• 15 Mukhopadhyay A, Farrell T, Fraser R B, Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials.  Am J Obstet Gynecol. 2007;  197 447-56
• 16 Mullins P, Sharplin P, Yki-Jarvinen H, Riddle M C, Haring H U. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.  Clin Ther. 2007;  29 1607-19
• 17 Nichols G A, Koo Y H, Shah S N. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy.  J Gen Intern Med. 2007;  22 453-8
• 18 Owens D R, Zinman B, Bolli G B. Insulins today and beyond.  Lancet. 2001;  358 739-46
• 19 Pampanelli S, Fanelli C, Lalli C. et al . Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia.  Diabetologia. 1996;  39 677-86
• 20 Peyrot M, Rubin R R, Lauritzen T The International DAWN Advisory Panel. et al . Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.  Diabetes Care. 2005;  28 2673-9
• 21 Phillip M, Battelino T, Rodriguez H. et al . Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetes Care. 2007;  30 1653-62
• 22 Porcellati F, Rossetti P, Busciantella N R. et al . Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs Glargin and detemir at steady state in type 1 diabetes.  Diabetes Care. 2007;  30 2447-52
• 23 Rathmann W, Haastert B, Icks A. et al . High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000.  Diabetologia. 2003;  46 182-9
• 24 Rubino A, McQuay L J, Gough S C, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes.  Diabet Med. 2007;  24 1412-8
• 25 Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.  Diabetes Care. 2000;  23 Suppl 2 B21-9
• 26 Stratton I M, Adler A I, Neil H A. et al . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35).  BMJ. 2000;  321 405-12
• 27 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 977-86
• 28 Umpierrez G E, Smiley D, Zisman A. et al . Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).  Diabetes Care. 2007;  30 2181-6
• 29 Van den Berghe G. Insulin therapy in the intensive care unit should be targeted to maintain blood glucose between 4.4 mmol/l and 6.1 mmol/l.  Diabetologia. 2007 Nov 27 [Epub ahead of print];